Evofem Biosciences Inc (NASDAQ:EVFM) recently announced that the clinical findings from its Phase 3 AMPOWER study evaluating Phexxi as contraceptive have been published in a peer-reviewed international journal called Contraception. The journal published the findings from the AMPOWER study of Phexxi in its website version of the journal. However, it...